WallStSmart

Thermo Fisher Scientific Inc (TMO)vsWaters Corporation (WAT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 920% more annual revenue ($47.35B vs $4.64B). TMO leads profitability with a 14.9% profit margin vs 3.6%. WAT appears more attractively valued with a PEG of 1.78. TMO earns a higher WallStSmart Score of 56/100 (C).

TMO

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 6.5Value: 4.3Quality: 6.0
Piotroski: 3/9Altman Z: 2.13

WAT

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 5.0Value: 2.7Quality: 7.0
Piotroski: 2/9Altman Z: 4.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for TMO.

WATSignificantly Overvalued (-44.6%)

Margin of Safety

-44.6%

Fair Value

$227.71

Current Price

$453.08

$225.37 premium

UndervaluedFair: $227.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TMO3 strengths · Avg: 8.7/10
Market CapQuality
$258.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

WAT3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
113.4%10/10

Revenue surging 113.4% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
2.034/10

Expensive relative to growth rate

P/E RatioValuation
36.8x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WAT4 concerns · Avg: 3.3/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

Return on EquityProfitability
1.1%3/10

ROE of 1.1% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 113.4% demonstrates continued momentum.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 121.5x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

TMO profiles as a value stock while WAT is a hypergrowth play — different risk/reward profiles.

WAT carries more volatility with a beta of 1.15 — expect wider price swings.

WAT is growing revenue faster at 113.4% — sustainability is the question.

TMO generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (56/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?